Oklahoma 2022 Regular Session

Oklahoma Senate Bill SB511 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
	3	+	SB511 HFLR Page 1
	4	+	BOLD FACE denotes Committee Amendments. 1
	5	+	2
	6	+	3
	7	+	4
	8	+	5
	9	+	6
	10	+	7
	11	+	8
	12	+	9
	13	+	10
	14	+	11
	15	+	12
	16	+	13
	17	+	14
	18	+	15
	19	+	16
	20	+	17
	21	+	18
	22	+	19
	23	+	20
	24	+	21
	25	+	22
	26	+	23
	27	+	24
3	28
4		-	An Act
5		-	ENROLLED SENATE
	29	+	HOUSE OF REPRESENTATIVES - FLOOR VERSION
	30	+
	31	+	STATE OF OKLAHOMA
	32	+
	33	+	1st Session of the 58th Legislature (2021)
	34	+
	35	+	ENGROSSED SENATE
6	36		BILL NO. 511 By: Montgomery, Hicks and
7	37		Dossett (J.A.) of the
8	38		Senate
9	39
10	40		and
11	41
12		-	Bush, Pae, Waldron ~~and~~
13		-	~~McEntire of~~ the House
	42	+	Bush, Pae and Waldron of
	43	+	the House
14	44
15	45
16	46
17	47
18	48		An Act relating to controlled dangerous substances;
19	49		amending 63 O.S. 2011, Section 2 -101, as last amended
20	50		by Section 1, Chapter 101, O.S.L. 2020 (63 O.S. Supp.
21	51		2020, Section 2-101), which relates to definitions;
22	52		adding and modifying definitions; amending 63 O.S.
23	53		2011, Section 2-101.1, which relates to drug
24	54		paraphernalia; providing exception; authorizing
25	55		certain entities to engage in harm -reduction
26	56		services; requiring registration with the State
27	57		Department of Health; providing for certain allowable
28	58		activities; providing rep orting requirements;
29	59		directing promulgation of rules; providing for
30	60		codification; and declaring an emergency .
31	61
32	62
33	63
34	64
35	65
36		-	SUBJECT: Harm-reduction services
37		-
38	66		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
39		-
40	67		SECTION 1. AMENDATORY 63 O.S. 2011, Section 2 -101, as
41	68		last amended by Section 1, Chapter 101, O.S.L. 2020 (63 O.S. Supp.
42	69		2020, Section 2-101), is amended to read as follows:
43	70
	71	+	SB511 HFLR Page 2
	72	+	BOLD FACE denotes Committee Amendments. 1
	73	+	2
	74	+	3
	75	+	4
	76	+	5
	77	+	6
	78	+	7
	79	+	8
	80	+	9
	81	+	10
	82	+	11
	83	+	12
	84	+	13
	85	+	14
	86	+	15
	87	+	16
	88	+	17
	89	+	18
	90	+	19
	91	+	20
	92	+	21
	93	+	22
	94	+	23
	95	+	24
	96	+
44	97		Section 2-101. As used in the Uniform Controlled Dangerous
45	98		Substances Act:
46		-
47		-
48		-	ENR. S. B. NO. 511 Page 2
49	99		1. “Administer” means the direct application of a controlled
50	100		dangerous substance, whether by injection, inhalation, ingestion or
51	101		any other means, to the body of a patient, animal or research
52	102		subject by:
53		-
54	103		a. a practitioner (or, in the presence of the
55	104		practitioner, by the authorized agent of the
56	105		practitioner), or
57		-
58	106		b. the patient or research subject at the direction and
59	107		in the presence of the practitioner;
60		-
61	108		2. “Agent” means a peace officer appointed by and who acts on
62	109		behalf of the Director of the Oklahoma State Bureau of Narcotics and
63	110		Dangerous Drugs Control or an authorized person who acts on behalf
64	111		of or at the direction of a person who manufactures, distributes,
65	112		dispenses, prescribes, administers or uses for scientific purposes
66	113		controlled dangerous substances but does not include a common or
67	114		contract carrier, public warehou ser or employee thereof, or a person
68	115		required to register under the Uniform Controlled Dangerous
69	116		Substances Act;
70		-
71	117		3. “Board” means the Advisory Board to the Director of the
72	118		Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
73		-
74	119		4. “Bureau” means the Oklahoma State Bureau of Narcotics and
75	120		Dangerous Drugs Control;
	121	+
	122	+	SB511 HFLR Page 3
	123	+	BOLD FACE denotes Committee Amendments. 1
	124	+	2
	125	+	3
	126	+	4
	127	+	5
	128	+	6
	129	+	7
	130	+	8
	131	+	9
	132	+	10
	133	+	11
	134	+	12
	135	+	13
	136	+	14
	137	+	15
	138	+	16
	139	+	17
	140	+	18
	141	+	19
	142	+	20
	143	+	21
	144	+	22
	145	+	23
	146	+	24
76	147
77	148		5. “Coca leaves” includes cocaine and any compound,
78	149		manufacture, salt, derivative, mixture or preparation of coca
79	150		leaves, except derivatives of coca leaves which do not contain
80	151		cocaine or ecgonine;
81		-
82	152		6. “Commissioner” or “Director” means the Director of the
83	153		Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
84		-
85	154		7. “Control” means to add, remove or change the placement of a
86	155		drug, substance or immediate precursor under the Uniform C ontrolled
87	156		Dangerous Substances Act;
88		-
89	157		8. “Controlled dangerous substance ” means a drug, substance or
90	158		immediate precursor in Schedules I through V of the Uniform
91		-
92		-	ENR. S. B. NO. 511 Page 3
93	159		Controlled Dangerous Substances Act or any drug, substance or
94	160		immediate precursor listed either temporarily or permanently as a
95	161		federally controlled substance. Any conflict between state and
96	162		federal law with regard to the particular schedule in which a
97	163		substance is listed shall be resolved in favor of state law;
98		-
99	164		9. “Counterfeit substance ” means a controlled substance which,
100	165		or the container or labeling of which without authorization, bears
101	166		the trademark, trade name or other identifying marks, imprint,
102	167		number or device or any likeness thereof of a manufacturer,
103	168		distributor or dispenser other than the person who in fact
104	169		manufactured, distributed or dispensed the substance;
105		-
106	170		10. “Deliver” or “delivery” means the actual, constructive or
107	171		attempted transfer from one person to another of a controlled
	172	+
	173	+	SB511 HFLR Page 4
	174	+	BOLD FACE denotes Committee Amendments. 1
	175	+	2
	176	+	3
	177	+	4
	178	+	5
	179	+	6
	180	+	7
	181	+	8
	182	+	9
	183	+	10
	184	+	11
	185	+	12
	186	+	13
	187	+	14
	188	+	15
	189	+	16
	190	+	17
	191	+	18
	192	+	19
	193	+	20
	194	+	21
	195	+	22
	196	+	23
	197	+	24
	198	+
108	199		dangerous substance or drug paraphernalia, whether or not there is
109	200		an agency relationship;
110		-
111	201		11. “Dispense” means to deliver a controlled dangerous
112	202		substance to an ultimate user or human research subject by or
113	203		pursuant to the lawful order of a practitioner , including the
114	204		prescribing, administering, packaging, lab eling or compounding
115	205		necessary to prepare the substance for such distribution.
116	206		“Dispenser” is a practitioner who delivers a controlled dangerous
117	207		substance to an ultimate user or human research subject;
118		-
119	208		12. “Distribute” means to deliver other than by admi nistering
120	209		or dispensing a controlled dangerous substance;
121		-
122	210		13. “Distributor” means a commercial entity engaged in the
123	211		distribution or reverse distribution of narcotics and dangerous
124	212		drugs and who complies with all regulations promulgated by the
125	213		federal Drug Enforcement Administration and the Oklahoma State
126	214		Bureau of Narcotics and Dangerous Drugs Control;
127		-
128	215		14. “Drug” means articles:
129		-
130	216		a. recognized in the official United States
131	217		Pharmacopoeia, official Homeopathic Pharmacopoeia of
132	218		the United States, or official National Formulary, or
133	219		any supplement to any of them,
134		-
135		-
136		-	ENR. S. B. NO. 511 Page 4
137	220		b. intended for use in the diagnosis, cure, mitigation,
138	221		treatment or prevention of disease in man or other
139	222		animals,
140	223
	224	+	SB511 HFLR Page 5
	225	+	BOLD FACE denotes Committee Amendments. 1
	226	+	2
	227	+	3
	228	+	4
	229	+	5
	230	+	6
	231	+	7
	232	+	8
	233	+	9
	234	+	10
	235	+	11
	236	+	12
	237	+	13
	238	+	14
	239	+	15
	240	+	16
	241	+	17
	242	+	18
	243	+	19
	244	+	20
	245	+	21
	246	+	22
	247	+	23
	248	+	24
	249	+
141	250		c. other than food, intended to affect the structure or
142	251		any function of the body of m an or other animals, and
143		-
144	252		d. intended for use as a component of any article
145	253		specified in this paragraph;
146		-
147	254		provided, however, the term “drug” does not include devices or their
148	255		components, parts or accessories;
149		-
150	256		15. “Drug-dependent person” means a person who i s using a
151	257		controlled dangerous substance and who is in a state of psychic or
152	258		physical dependence, or both, arising from administration of that
153	259		controlled dangerous substance on a continuous basis. Drug
154	260		dependence is characterized by behavioral and other r esponses which
155	261		include a strong compulsion to take the substance on a continuous
156	262		basis in order to experience its psychic effects, or to avoid the
157	263		discomfort of its absence;
158		-
159	264		16. “Home care agency” means any sole proprietorship,
160	265		partnership, association, c orporation, or other organization which
161	266		administers, offers, or provides home care services, for a fee or
162	267		pursuant to a contract for such services, to clients in their place
163	268		of residence;
164		-
165	269		17. “Home care services” means skilled or personal care
166	270		services provided to clients in their place of residence for a fee;
167		-
168	271		18. “Hospice” means a centrally administered, nonprofit or
169	272		profit, medically directed, nurse -coordinated program which provides
170	273		a continuum of home and inpatient care for the terminally ill
	274	+
	275	+	SB511 HFLR Page 6
	276	+	BOLD FACE denotes Committee Amendments. 1
	277	+	2
	278	+	3
	279	+	4
	280	+	5
	281	+	6
	282	+	7
	283	+	8
	284	+	9
	285	+	10
	286	+	11
	287	+	12
	288	+	13
	289	+	14
	290	+	15
	291	+	16
	292	+	17
	293	+	18
	294	+	19
	295	+	20
	296	+	21
	297	+	22
	298	+	23
	299	+	24
	300	+
171	301		patient and the patient’s family. Such term shall also include a
172	302		centrally administered, nonprofit or profit, medically directed,
173	303		nurse-coordinated program if such program is licensed pursuant to
174	304		the provisions of the Uniform Controlled Dangerous Substances Act.
175	305		A hospice program offers palliative and supportive care to meet the
176	306		special needs arising out of the physical, emotional and spiritual
177	307		stresses which are experienced during the final stages of illness
178	308		and during dying and bereavement. This care is availa ble twenty-
179		-
180		-	ENR. S. B. NO. 511 Page 5
181	309		four (24) hours a day, seven (7) days a week, and is provided on the
182	310		basis of need, regardless of ability to pay. “Class A” Hospice
183	311		refers to Medicare certified hospices. “Class B” refers to all
184	312		other providers of hospice services;
185		-
186	313		19. “Imitation controlled substance ” means a substance that is
187	314		not a controlled dangerous substance, which by dosage unit
188	315		appearance, color, shape, size, markings or by representations made,
189	316		would lead a reasonable person to believe that the substance is a
190	317		controlled dangerous substance. In the event the appearance of the
191	318		dosage unit is not reasonably sufficient to establish that the
192	319		substance is an “imitation controlled substance ”, the court or
193	320		authority concerned should consider, in addition to all other
194	321		factors, the following factors as related to “representations made ”
195	322		in determining whether the substance is an “imitation controlled
196	323		substance”:
197	324
	325	+	SB511 HFLR Page 7
	326	+	BOLD FACE denotes Committee Amendments. 1
	327	+	2
	328	+	3
	329	+	4
	330	+	5
	331	+	6
	332	+	7
	333	+	8
	334	+	9
	335	+	10
	336	+	11
	337	+	12
	338	+	13
	339	+	14
	340	+	15
	341	+	16
	342	+	17
	343	+	18
	344	+	19
	345	+	20
	346	+	21
	347	+	22
	348	+	23
	349	+	24
	350	+
198	351		a. statements made by an owner or by any other person in
199	352		control of the substance concerning the nature of the
200	353		substance, or its use or effect,
201		-
202	354		b. statements made to the recipient that the substance
203	355		may be resold for inordinate profit,
204		-
205	356		c. whether the substance is packaged in a manner normally
206	357		used for illicit controlled substances,
207		-
208	358		d. evasive tactics or actions utilized by the owner or
209	359		person in control of the substance to avoid detection
210	360		by law enforcement authorities,
211		-
212	361		e. prior convictions, if any, of an owner, or any other
213	362		person in control of the object, under state or
214	363		federal law related to controlled substances or fraud ,
215	364		and
216		-
217	365		f. the proximity of the substances to controlled
218	366		dangerous substances;
219		-
220	367		20. “Immediate precursor” means a substance which the Director
221	368		has found to be and by regulation designates as being the principal
222	369		compound commonly used or produced primarily fo r use, and which is
223		-
224		-	ENR. S. B. NO. 511 Page 6
225	370		an immediate chemical intermediary used, or likely to be used, in
226	371		the manufacture of a controlled dangerous substance, the control of
227	372		which is necessary to prevent, curtail or limit such manufacture;
228		-
229	373		21. “Laboratory” means a laboratory approved by the Director as
230	374		proper to be entrusted with the custody of controlled dangerous
	375	+
	376	+	SB511 HFLR Page 8
	377	+	BOLD FACE denotes Committee Amendments. 1
	378	+	2
	379	+	3
	380	+	4
	381	+	5
	382	+	6
	383	+	7
	384	+	8
	385	+	9
	386	+	10
	387	+	11
	388	+	12
	389	+	13
	390	+	14
	391	+	15
	392	+	16
	393	+	17
	394	+	18
	395	+	19
	396	+	20
	397	+	21
	398	+	22
	399	+	23
	400	+	24
	401	+
231	402		substances and the use of controlled dangerous substances for
232	403		scientific and medical purposes and for purposes of instruction;
233		-
234	404		22. “Manufacture” means the production, preparation,
235	405		propagation, compounding or processing of a controlled dangerous
236	406		substance, either directly or indirectly by extraction from
237	407		substances of natural or synthetic origin, or independently by means
238	408		of chemical synthesis or by a combination of extraction and chemical
239	409		synthesis. “Manufacturer” includes any person who packages,
240	410		repackages or labels any container of any controlled dangerous
241	411		substance, except practitioners who dispense or compound
242	412		prescription orders for delivery to the ultimate c onsumer;
243		-
244	413		23. “Marijuana” means all parts of the plant Cannabis sativa
245	414		L., whether growing or not; the seeds thereof; the resin extracted
246	415		from any part of such plant; and every compound, manufacture, salt,
247	416		derivative, mixture or preparation of such plant, its seeds or
248	417		resin, but shall not include:
249		-
250	418		a. the mature stalks of such plant or fiber produced from
251	419		such stalks,
252		-
253	420		b. oil or cake made from the seeds of such plant ,
254	421		including cannabidiol derived from the seeds of the
255	422		marijuana plant,
256		-
257	423		c. any other compound, manufacture, salt, derivative,
258	424		mixture or preparation of such mature stalks (except
	425	+
	426	+	SB511 HFLR Page 9
	427	+	BOLD FACE denotes Committee Amendments. 1
	428	+	2
	429	+	3
	430	+	4
	431	+	5
	432	+	6
	433	+	7
	434	+	8
	435	+	9
	436	+	10
	437	+	11
	438	+	12
	439	+	13
	440	+	14
	441	+	15
	442	+	16
	443	+	17
	444	+	18
	445	+	19
	446	+	20
	447	+	21
	448	+	22
	449	+	23
	450	+	24
	451	+
259	452		the resin extracted therefrom) , including cannabidiol
260	453		derived from mature stalks, fiber, oil or cake,
261		-
262	454		d. the sterilized seed of such plant which is incapable
263	455		of germination,
264		-
265	456		e. for any person participating in a clinical trial to
266	457		administer cannabidiol for the treatment of severe
267		-
268		-	ENR. S. B. NO. 511 Page 7
269	458		forms of epilepsy pursuant to Section 2 -802 of this
270	459		title, a drug or substance approved by the federal
271	460		Food and Drug Administration for use by those
272	461		participants,
273		-
274	462		f. for any person or the parents, legal guardians or
275	463		caretakers of the person who have received a written
276	464		certification from a physician licensed in this state
277	465		that the person has been diagnosed by a physician as
278	466		having Lennox-Gastaut syndrome, Dravet syndrome, also
279	467		known as Severe Myoclonic Epilepsy of Infancy, or any
280	468		other severe form of epilepsy that is not adequately
281	469		treated by traditional medical therapies, spasticity
282	470		due to multiple sclerosis or due to paraplegia,
283	471		intractable nausea and vomiting, appetite stimulation
284	472		with chronic wasting diseases, the substance
285	473		cannabidiol, a nonpsychoactive cannabinoid, found in
286	474		the plant Cannabis sativa L. or any other preparation
287	475		thereof, that has a tetrahydrocannabinol concentration
	476	+
	477	+	SB511 HFLR Page 10
	478	+	BOLD FACE denotes Committee Amendments. 1
	479	+	2
	480	+	3
	481	+	4
	482	+	5
	483	+	6
	484	+	7
	485	+	8
	486	+	9
	487	+	10
	488	+	11
	489	+	12
	490	+	13
	491	+	14
	492	+	15
	493	+	16
	494	+	17
	495	+	18
	496	+	19
	497	+	20
	498	+	21
	499	+	22
	500	+	23
	501	+	24
	502	+
288	503		of not more than three-tenths of one percent (0.3%)
289	504		and that is delivered to the patient in the form of a
290	505		liquid,
291		-
292	506		g. any federal Food and Drug Administration -approved
293	507		cannabidiol drug or substance, or
294		-
295	508		h. industrial hemp, from the plant Cannabis sativa L. and
296	509		any part of such plant, whether growing or not, with a
297	510		delta-9 tetrahydrocannabinol concentration of not more
298	511		than three-tenths of one percent (0.3%) on a dry
299	512		weight basis which shall only be grown pursuant to the
300	513		Oklahoma Industrial Hemp Program and may be shipped
301	514		intrastate and interstate;
302		-
303	515		24. “Medical purpose” means an intention to utilize a
304	516		controlled dangerous substance for physical or mental treatment, for
305	517		diagnosis, or for the prevention of a disease condition not in
306	518		violation of any state or federal law and not for the purpose of
307	519		satisfying physiological or psychological dependence or other abuse;
308		-
309	520		25. “Mid-level practitioner” means an Advanced Practice
310	521		Registered Nurse as defined and within parameters specified in
311		-
312		-	ENR. S. B. NO. 511 Page 8
313	522		Section 567.3a of Title 59 of the Oklahoma Statu tes, or a certified
314	523		animal euthanasia technician as defined in Section 698.2 of Title 59
315	524		of the Oklahoma Statutes, or an animal control officer registered by
316	525		the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
317	526		under subsection B of Section 2 -301 of this title within the
	527	+
	528	+	SB511 HFLR Page 11
	529	+	BOLD FACE denotes Committee Amendments. 1
	530	+	2
	531	+	3
	532	+	4
	533	+	5
	534	+	6
	535	+	7
	536	+	8
	537	+	9
	538	+	10
	539	+	11
	540	+	12
	541	+	13
	542	+	14
	543	+	15
	544	+	16
	545	+	17
	546	+	18
	547	+	19
	548	+	20
	549	+	21
	550	+	22
	551	+	23
	552	+	24
	553	+
318	554		parameters of such officer ’s duty duties under Sections 501 through
319	555		508 of Title 4 of the Oklahoma Statutes;
320		-
321	556		26. “Narcotic drug” means any of the following, whether
322	557		produced directly or indirectly by extraction from substance s of
323	558		vegetable origin, or independently by means of chemical synthesis,
324	559		or by a combination of extraction and chemical synthesis:
325		-
326	560		a. opium, coca leaves and opiates,
327		-
328	561		b. a compound, manufacture, salt, derivative or
329	562		preparation of opium, coca leaves or opiate s,
330		-
331	563		c. cocaine, its salts, optical and geometric isomers, and
332	564		salts of isomers,
333		-
334	565		d. ecgonine, its derivatives, their salts, isomers and
335	566		salts of isomers, and
336		-
337	567		e. a substance, and any compound, manufacture, salt,
338	568		derivative or preparation thereof, which is che mically
339	569		identical with any of the substances referred to in
340	570		subparagraphs a through d of this paragraph, except
341	571		that the words “narcotic drug” as used in Section 2 -
342	572		101 et seq. of this title shall not include
343	573		decocainized coca leaves or extracts of coca lea ves,
344	574		which extracts do not contain cocaine or ecgonine;
345		-
346	575		27. “Opiate” or “opioid” means any Schedule II, III, IV or V
347	576		substance having an addiction -forming or addiction -sustaining
348	577		liability similar to morphine or being capable of conversion into a
	578	+
	579	+	SB511 HFLR Page 12
	580	+	BOLD FACE denotes Committee Amendments. 1
	581	+	2
	582	+	3
	583	+	4
	584	+	5
	585	+	6
	586	+	7
	587	+	8
	588	+	9
	589	+	10
	590	+	11
	591	+	12
	592	+	13
	593	+	14
	594	+	15
	595	+	16
	596	+	17
	597	+	18
	598	+	19
	599	+	20
	600	+	21
	601	+	22
	602	+	23
	603	+	24
	604	+
349	605		drug having such addiction-forming or addiction -sustaining
350	606		liability. The terms do not include, unless specifically designated
351	607		as controlled under the Uniform Controlled Dangerous Substances Act,
352	608		the dextrorotatory isomer of 3 -methoxy-n-methyl-morphinan and its
353	609		salts (dextromethorphan). The terms do include the racemic and
354	610		levorotatory forms;
355		-
356		-	ENR. S. B. NO. 511 Page 9
357		-
358	611		28. “Opium poppy” means the plant of the species Papaver
359	612		somniferum L., except the seeds thereof;
360		-
361	613		29. “Peace officer” means a police officer, sheriff, deputy
362	614		sheriff, district attorney’s investigator, investigator from the
363	615		Office of the Attorney General, or any other person elected or
364	616		appointed by law to enforce any of the criminal laws of this state
365	617		or of the United States;
366		-
367	618		30. “Person” means an individual, corporation, g overnment or
368	619		governmental subdivision or agency, business trust, estate, trust,
369	620		partnership or association, or any other legal entity;
370		-
371	621		31. “Poppy straw” means all parts, except the seeds, of the
372	622		opium poppy, after mowing;
	623	+	32. “Practitioner” means:
	624	+	a. (1) a medical doctor or osteopathic physician,
	625	+	(2) a dentist,
	626	+	(3) a podiatrist,
	627	+	(4) an optometrist,
	628	+	(5) a veterinarian,
373	629
374		-	32. “Practitioner” means:
375		-
376		-	a. (1) a medical doctor or osteopathic physician,
377		-
378		-	(2) a dentist,
379		-
380		-	(3) a podiatrist,
381		-
382		-	(4) an optometrist,
383		-
384		-	(5) a veterinarian,
	630	+	SB511 HFLR Page 13
	631	+	BOLD FACE denotes Committee Amendments. 1
	632	+	2
	633	+	3
	634	+	4
	635	+	5
	636	+	6
	637	+	7
	638	+	8
	639	+	9
	640	+	10
	641	+	11
	642	+	12
	643	+	13
	644	+	14
	645	+	15
	646	+	16
	647	+	17
	648	+	18
	649	+	19
	650	+	20
	651	+	21
	652	+	22
	653	+	23
	654	+	24
385	655
386	656		(6) a physician assistant or Advanced Practice
387	657		Registered Nurse under the supervision of a
388	658		licensed medical doctor or osteopathic physician ,
389		-
390	659		(7) a scientific investigator, or
391		-
392	660		(8) any other person,
393		-
394	661		licensed, registered or otherwise permitted to
395	662		prescribe, distribute, dispense, conduct research with
396	663		respect to, use for scientific purposes or administer
397	664		a controlled dangerous substance in the co urse of
398	665		professional practice or research in this state, or
399		-
400		-	ENR. S. B. NO. 511 Page 10
401		-
402	666		b. a pharmacy, hospital, laboratory or other institution
403	667		licensed, registered or otherwise permitted to
404	668		distribute, dispense, conduct research with respect
405	669		to, use for scientific purposes or admin ister a
406	670		controlled dangerous substance in the course of
407	671		professional practice or research in this state;
408		-
409	672		33. “Production” includes the manufacture, planting,
410	673		cultivation, growing or harvesting of a controlled dangerous
411	674		substance;
412		-
413	675		34. “State” means the State of Oklahoma or any other state of
414	676		the United States;
415		-
416	677		35. “Ultimate user” means a person who lawfully possesses a
417	678		controlled dangerous substance for the person ’s own use or for the
418	679		use of a member of the person ’s household or for administration to
	680	+
	681	+	SB511 HFLR Page 14
	682	+	BOLD FACE denotes Committee Amendments. 1
	683	+	2
	684	+	3
	685	+	4
	686	+	5
	687	+	6
	688	+	7
	689	+	8
	690	+	9
	691	+	10
	692	+	11
	693	+	12
	694	+	13
	695	+	14
	696	+	15
	697	+	16
	698	+	17
	699	+	18
	700	+	19
	701	+	20
	702	+	21
	703	+	22
	704	+	23
	705	+	24
	706	+
419	707		an animal owned by the person or by a member of the person ’s
420	708		household;
421		-
422	709		36. “Drug paraphernalia” means all equipment, products and
423	710		materials of any kind which are used, intended for use, or fashioned
424	711		specifically for use in planting, propagating, cultivating, growing,
425	712		harvesting, manufacturing, compounding, converting, producing,
426	713		processing, preparing, testing, analyzing, packaging, repackaging,
427	714		storing, containing, concealing, injecting, ingesting, inhaling or
428	715		otherwise introducing into the human body, a cont rolled dangerous
429	716		substance in violation of the Uniform Controlled Dangerous
430	717		Substances Act including, but not limited to:
431		-
432	718		a. kits used, intended for use, or fashioned specifically
433	719		for use in planting, propagating, cultivating, growing
434	720		or harvesting of any species of plant which is a
435	721		controlled dangerous substance or from which a
436	722		controlled dangerous substance can be derived,
437		-
438	723		b. kits used, intended for use, or fashioned specifically
439	724		for use in manufacturing, compounding, converting,
440	725		producing, processing or preparing controlled
441	726		dangerous substances,
442		-
443		-
444		-	ENR. S. B. NO. 511 Page 11
445	727		c. isomerization devices used, intended for use, or
446	728		fashioned specifically for use in increasing the
447	729		potency of any species of plant which is a controlled
448	730		dangerous substance,
449	731
	732	+	SB511 HFLR Page 15
	733	+	BOLD FACE denotes Committee Amendments. 1
	734	+	2
	735	+	3
	736	+	4
	737	+	5
	738	+	6
	739	+	7
	740	+	8
	741	+	9
	742	+	10
	743	+	11
	744	+	12
	745	+	13
	746	+	14
	747	+	15
	748	+	16
	749	+	17
	750	+	18
	751	+	19
	752	+	20
	753	+	21
	754	+	22
	755	+	23
	756	+	24
	757	+
450	758		d. testing equipment used, intended f or use, or fashioned
451	759		specifically for use in identifying, or in analyzing
452	760		the strength, effectiveness or purity of controlled
453	761		dangerous substances,
454		-
455	762		e. scales and balances used, intended for use, or
456	763		fashioned specifically for use in weighing or
457	764		measuring controlled dangerous substances,
458		-
459	765		f. diluents and adulterants, such as quinine
460	766		hydrochloride, mannitol, mannite, dextrose and
461	767		lactose, used, intended for use, or fashioned
462	768		specifically for use in cutting controlled dangerous
463	769		substances,
464		-
465	770		g. separation gins and sifters used, intended for use, or
466	771		fashioned specifically for use in removing twigs and
467	772		seeds from, or in otherwise cleaning or refining,
468	773		marijuana,
469		-
470	774		h. blenders, bowls, containers, spoons and mixing devices
471	775		used, intended for use, or fashioned specificall y for
472	776		use in compounding controlled dangerous substances,
473		-
474	777		i. capsules, balloons, envelopes and other containers
475	778		used, intended for use, or fashioned specifically for
476	779		use in packaging small quantities of controlled
477	780		dangerous substances,
478	781
	782	+	SB511 HFLR Page 16
	783	+	BOLD FACE denotes Committee Amendments. 1
	784	+	2
	785	+	3
	786	+	4
	787	+	5
	788	+	6
	789	+	7
	790	+	8
	791	+	9
	792	+	10
	793	+	11
	794	+	12
	795	+	13
	796	+	14
	797	+	15
	798	+	16
	799	+	17
	800	+	18
	801	+	19
	802	+	20
	803	+	21
	804	+	22
	805	+	23
	806	+	24
	807	+
479	808		j. containers and other objects used, intended for use,
480	809		or fashioned specifically for use in parenterally
481	810		injecting controlled dangerous substances into the
482	811		human body,
483		-
484	812		k. hypodermic syringes, needles and other objects used,
485	813		intended for use, or fashioned specifically for use in
486	814		parenterally injecting controlled dangerous substances
487		-
488		-	ENR. S. B. NO. 511 Page 12
489	815		into the human body except as authorized by Section 3
490	816		of this act,
491		-
492	817		l. objects used, intended for use, or fashioned
493	818		specifically for use in ingesting, inhaling or
494	819		otherwise introducing marijuana, co caine, hashish or
495	820		hashish oil into the human body, such as:
496		-
497	821		(1) metal, wooden, acrylic, glass, stone, plastic or
498	822		ceramic pipes with or without screens, permanent
499	823		screens, hashish heads or punctured metal bowls,
500		-
501	824		(2) water pipes,
502		-
503	825		(3) carburetion tubes and de vices,
504		-
505	826		(4) smoking and carburetion masks,
506		-
507	827		(5) roach clips, meaning objects used to hold burning
508	828		material, such as a marijuana cigarette, that has
509	829		become too small or too short to be held in the
510	830		hand,
511		-
512	831		(6) miniature cocaine spoons and cocaine vials,
513	832
	833	+	SB511 HFLR Page 17
	834	+	BOLD FACE denotes Committee Amendments. 1
	835	+	2
	836	+	3
	837	+	4
	838	+	5
	839	+	6
	840	+	7
	841	+	8
	842	+	9
	843	+	10
	844	+	11
	845	+	12
	846	+	13
	847	+	14
	848	+	15
	849	+	16
	850	+	17
	851	+	18
	852	+	19
	853	+	20
	854	+	21
	855	+	22
	856	+	23
	857	+	24
	858	+
514	859		(7) chamber pipes,
515		-
516	860		(8) carburetor pipes,
517		-
518	861		(9) electric pipes,
519		-
520	862		(10) air-driven pipes,
521		-
522	863		(11) chillums,
523		-
524	864		(12) bongs, or
525		-
526	865		(13) ice pipes or chillers,
527		-
528	866		m. all hidden or novelty pipes, and
529		-
530		-
531		-	ENR. S. B. NO. 511 Page 13
532	867		n. any pipe that has a tobacco bowl or chamber of less
533	868		than one-half (1/2) inch in dia meter in which there is
534	869		any detectable residue of any controlled dangerous
535	870		substance as defined in this section or any other
536	871		substances not legal for possession or use;
537		-
538	872		provided, however, the term “drug paraphernalia” shall not include
539	873		separation gins inte nded for use in preparing tea or spice, clamps
540	874		used for constructing electrical equipment, water pipes designed for
541	875		ornamentation in which no detectable amount of an illegal substance
542	876		is found or pipes designed and used solely for smoking tobacco,
543	877		traditional pipes of an American Indian tribal religious ceremony,
544	878		or antique pipes that are thirty (30) years of age or older;
545		-
546	879		37. a. “Synthetic controlled substance ” means a substance:
547		-
548	880		(1) the chemical structure of which is substantially
549	881		similar to the chemical structure of a controlled
550	882		dangerous substance in Schedule I or II,
	883	+
	884	+	SB511 HFLR Page 18
	885	+	BOLD FACE denotes Committee Amendments. 1
	886	+	2
	887	+	3
	888	+	4
	889	+	5
	890	+	6
	891	+	7
	892	+	8
	893	+	9
	894	+	10
	895	+	11
	896	+	12
	897	+	13
	898	+	14
	899	+	15
	900	+	16
	901	+	17
	902	+	18
	903	+	19
	904	+	20
	905	+	21
	906	+	22
	907	+	23
	908	+	24
551	909
552	910		(2) which has a stimulant, depressant, or
553	911		hallucinogenic effect on the central nervous
554	912		system that is substantially similar to or
555	913		greater than the stimulant, depressant or
556	914		hallucinogenic effect on the central nervous
557	915		system of a controlled dangerous substance in
558	916		Schedule I or II, or
559		-
560	917		(3) with respect to a particular person, which such
561	918		person represents or intends to have a stimulant,
562	919		depressant, or hallucinogenic effect on the
563	920		central nervous system that is substantially
564	921		similar to or greater than the stimulant,
565	922		depressant, or hallucinogenic effect on the
566	923		central nervous system of a controlled dangerous
567	924		substance in Schedule I or II.
568		-
569	925		b. The designation of gamma butyrolactone or any other
570	926		chemical as a precursor, pursuant to Section 2 -322 of
571	927		this title, does not preclude a finding pursuant to
572	928		subparagraph a of this paragraph that the chemical is
573	929		a synthetic controlled substance.
574		-
575		-	ENR. S. B. NO. 511 Page 14
576		-
577	930		c. “Synthetic controlled substance ” does not include:
578		-
579	931		(1) a controlled dangerous substance,
580		-
581	932		(2) any substance for which there is an approved new
582	933		drug application,
	934	+
	935	+	SB511 HFLR Page 19
	936	+	BOLD FACE denotes Committee Amendments. 1
	937	+	2
	938	+	3
	939	+	4
	940	+	5
	941	+	6
	942	+	7
	943	+	8
	944	+	9
	945	+	10
	946	+	11
	947	+	12
	948	+	13
	949	+	14
	950	+	15
	951	+	16
	952	+	17
	953	+	18
	954	+	19
	955	+	20
	956	+	21
	957	+	22
	958	+	23
	959	+	24
583	960
584	961		(3) with respect to a particular person any
585	962		substance, if an exemption is in effect for
586	963		investigational use, for that person under the
587	964		provisions of Section 505 of the Federal Food,
588	965		Drug and Cosmetic Act, Title 21 of the United
589	966		States Code, Section 355, to the extent conduct
590	967		with respect to such substance is pursuant to
591	968		such exemption, or
592		-
593	969		(4) any substance to the extent not intended for
594	970		human consumption before s uch an exemption takes
595	971		effect with respect to that substance.
596		-
597	972		d. Prima facie evidence that a substance containing
598	973		salvia divinorum has been enhanced, concentrated or
599	974		chemically or physically altered shall give rise to a
600	975		rebuttable presumption that the subs tance is a
601	976		synthetic controlled substance;
602		-
603	977		38. “Tetrahydrocannabinols ” means all substances that have been
604	978		chemically synthesized to emulate the tetrahydrocannabinols of
605	979		marijuana;
606		-
607	980		39. “Isomer” means the optical isomer, except as used in
608	981		subsections C and F of Section 2-204 of this title and paragraph 4
609	982		of subsection A of Section 2 -206 of this title. As used in
610	983		subsections C and F of Section 2 -204 of this title, “isomer” means
611	984		the optical, positional or geometric isomer. As used in paragraph 4
	985	+
	986	+	SB511 HFLR Page 20
	987	+	BOLD FACE denotes Committee Amendments. 1
	988	+	2
	989	+	3
	990	+	4
	991	+	5
	992	+	6
	993	+	7
	994	+	8
	995	+	9
	996	+	10
	997	+	11
	998	+	12
	999	+	13
	1000	+	14
	1001	+	15
	1002	+	16
	1003	+	17
	1004	+	18
	1005	+	19
	1006	+	20
	1007	+	21
	1008	+	22
	1009	+	23
	1010	+	24
	1011	+
612	1012		of subsection A of Section 2-206 of this title, the term “isomer”
613	1013		means the optical or geometric isomer;
614		-
615	1014		40. “Hazardous materials” means materials, whether solid,
616	1015		liquid or gas, which are toxic to human, animal, aquatic or plant
617		-
618		-	ENR. S. B. NO. 511 Page 15
619	1016		life, and the disposal of which mat erials is controlled by state or
620	1017		federal guidelines;
621		-
622	1018		41. “Anhydrous ammonia” means any substance that exhibits
623	1019		cryogenic evaporative behavior and tests positive for ammonia;
624		-
625	1020		42. “Acute pain” means pain, whether resulting from disease,
626	1021		accidental or intentional trauma or other cause, that the
627	1022		practitioner reasonably expects to last only a short period of time.
628	1023		“Acute pain” does not include chronic pain, pain being treated as
629	1024		part of cancer care, hospice or other end -of-life care, or pain
630	1025		being treated as part of palliative care;
631		-
632	1026		43. “Chronic pain” means pain that persists beyond the usual
633	1027		course of an acute disease or healing of an injury. “Chronic pain”
634	1028		may or may not be associated with an acute or chronic pathologic
635	1029		process that causes continuous or in termittent pain over months or
636	1030		years;
637		-
638	1031		44. “Initial prescription ” means a prescription issued to a
639	1032		patient who:
640		-
641	1033		a. has never previously been issued a prescription for
642	1034		the drug or its pharmaceutical equivalent in the past
643	1035		year, or
	1036	+
	1037	+	SB511 HFLR Page 21
	1038	+	BOLD FACE denotes Committee Amendments. 1
	1039	+	2
	1040	+	3
	1041	+	4
	1042	+	5
	1043	+	6
	1044	+	7
	1045	+	8
	1046	+	9
	1047	+	10
	1048	+	11
	1049	+	12
	1050	+	13
	1051	+	14
	1052	+	15
	1053	+	16
	1054	+	17
	1055	+	18
	1056	+	19
	1057	+	20
	1058	+	21
	1059	+	22
	1060	+	23
	1061	+	24
644	1062
645	1063		b. requires a prescription for the drug or its
646	1064		pharmaceutical equivalent due to a surgical procedure
647	1065		or new acute event and has previously had a
648	1066		prescription for the drug or its pharmaceutical
649	1067		equivalent within the past year.
650		-
651	1068		When determining whether a patient was previously issued a
652	1069		prescription for a drug or its pharmaceutical equivalent, the
653	1070		practitioner shall consult with the patient and review the medical
654	1071		record and prescription monitoring information of the patient;
655		-
656	1072		45. “Patient-provider agreement” means a written contract or
657	1073		agreement that is executed between a practitioner and a patient,
658	1074		prior to the commencement of treatment for chronic pain using an
659	1075		opioid drug as a means to:
660		-
661		-
662		-	ENR. S. B. NO. 511 Page 16
663	1076		a. explain the possible risk of development of physical
664	1077		or psychological dependence in the patient and prevent
665	1078		the possible development of addiction,
666		-
667	1079		b. document the understanding of both the practitioner
668	1080		and the patient regarding the patient -provider
669	1081		agreement of the patient,
670		-
671	1082		c. establish the rights of the patient in association
672	1083		with treatment and the obligations of the patient in
673	1084		relation to the responsible use, discontinuation of
674	1085		use, and storage of opioid drugs , including any
	1086	+
	1087	+	SB511 HFLR Page 22
	1088	+	BOLD FACE denotes Committee Amendments. 1
	1089	+	2
	1090	+	3
	1091	+	4
	1092	+	5
	1093	+	6
	1094	+	7
	1095	+	8
	1096	+	9
	1097	+	10
	1098	+	11
	1099	+	12
	1100	+	13
	1101	+	14
	1102	+	15
	1103	+	16
	1104	+	17
	1105	+	18
	1106	+	19
	1107	+	20
	1108	+	21
	1109	+	22
	1110	+	23
	1111	+	24
	1112	+
675	1113		restrictions on the refill of prescriptions or the
676	1114		acceptance of opioid prescriptions from practitioners,
677		-
678	1115		d. identify the specific medications and other modes of
679	1116		treatment, including physical therapy or exercise,
680	1117		relaxation or psychological counseling, that are
681	1118		included as a part of the patient -provider agreement,
682		-
683	1119		e. specify the measures the practitioner may employ to
684	1120		monitor the compliance of the patient including, but
685	1121		not limited to, random specimen screens and pill
686	1122		counts, and
687		-
688	1123		f. delineate the process for terminating the agreement ,
689	1124		including the consequences if the practitioner has
690	1125		reason to believe that the patient is not com plying
691	1126		with the terms of the agreement. Compliance with the
692	1127		“consent items” shall constitute a valid, informed
693	1128		consent for opioid therapy. The practitioner shall be
694	1129		held harmless from civil litigation for failure to
695	1130		treat pain if the event occurs because of nonadherence
696	1131		by the patient with any of the provisions of the
697	1132		patient-provider agreement;
698		-
699	1133		46. “Serious illness” means a medical illness or physical
700	1134		injury or condition that substantially affects quality of life for
701	1135		more than a short period of time. “Serious illness” includes, but
702	1136		is not limited to, Alzheimer ’s disease or related dementias, lung
	1137	+
	1138	+	SB511 HFLR Page 23
	1139	+	BOLD FACE denotes Committee Amendments. 1
	1140	+	2
	1141	+	3
	1142	+	4
	1143	+	5
	1144	+	6
	1145	+	7
	1146	+	8
	1147	+	9
	1148	+	10
	1149	+	11
	1150	+	12
	1151	+	13
	1152	+	14
	1153	+	15
	1154	+	16
	1155	+	17
	1156	+	18
	1157	+	19
	1158	+	20
	1159	+	21
	1160	+	22
	1161	+	23
	1162	+	24
	1163	+
703	1164		disease, cancer, heart failure, renal failure, liver failure or
704		-
705		-	ENR. S. B. NO. 511 Page 17
706	1165		chronic, unremitting or intractable pain such as neuropathic pain;
707	1166		and
708		-
709	1167		47. “Surgical procedure” means a procedure that is performed
710	1168		for the purpose of structurally altering the human body by incision
711	1169		or destruction of tissues as part of the practice of medicine. This
712	1170		term includes the diagnostic or therapeutic treatment of conditions
713	1171		or disease processes by use of instruments such as lasers,
714	1172		ultrasound, ionizing, radiation, scalpels, probes or needles that
715	1173		cause localized alteration or transportation of live human tissue by
716	1174		cutting, burning, vaporizing, freezing, suturing, probing or
717	1175		manipulating by closed reduction for major dislocations or
718	1176		fractures, or otherwise altering by any mechanical, thermal, light -
719	1177		based, electromagnetic or chemical means ; and
720		-
721	1178		48. “Harm-reduction services” means programs established to:
722		-
723	1179		a. reduce the spread of infectious d iseases related to
724	1180		injection drug use,
725		-
726	1181		b. reduce drug dependency, overdose deaths and associated
727	1182		complications, and
728		-
729	1183		c. increase safe recovery and disposal of used syringes
730	1184		and sharp waste.
731		-
732	1185		SECTION 2. AMENDATORY 63 O.S. 2011, Secti on 2-101.1, is
733	1186		amended to read as follows:
	1187	+
	1188	+	SB511 HFLR Page 24
	1189	+	BOLD FACE denotes Committee Amendments. 1
	1190	+	2
	1191	+	3
	1192	+	4
	1193	+	5
	1194	+	6
	1195	+	7
	1196	+	8
	1197	+	9
	1198	+	10
	1199	+	11
	1200	+	12
	1201	+	13
	1202	+	14
	1203	+	15
	1204	+	16
	1205	+	17
	1206	+	18
	1207	+	19
	1208	+	20
	1209	+	21
	1210	+	22
	1211	+	23
	1212	+	24
734	1213
735	1214		Section 2-101.1. In determining whether an object is “drug
736	1215		paraphernalia”, a court or jury shall consider, in addition to all
737	1216		other logically relevant factors, the following:
738		-
739	1217		1. Statements by an owner or by anyo ne in control of the object
740	1218		concerning its use;
741		-
742	1219		2. The proximity of the object, in time and space, to a direct
743	1220		violation of the Uniform Controlled Dangerous Substances Act;
744		-
745	1221		3. The proximity of the object to controlled dangerous
746	1222		substances;
747		-
748		-
749		-	ENR. S. B. NO. 511 Page 18
750	1223		4. The existence of any residue of controlled dangerous
751	1224		substances on the object;
752		-
753	1225		5. Direct or circumstantial evidence of the intent of an owner,
754	1226		or of anyone in control of the object, to deliver it to any person
755	1227		who intends to use the object to facilitate a violation of the
756	1228		Uniform Controlled Dangerous Substances Act. The innocence of an
757	1229		owner, or of anyone in control of the object, as to a direct
758	1230		violation of this act shall not prevent a finding that the object is
759	1231		intended for use, or fashioned specifically for use, as drug
760	1232		paraphernalia;
761		-
762	1233		6. Instructions, oral or written, provided with the object
763	1234		which either state directly or imply that the object is to be used
764	1235		for the consumption of controlled dangerous substances;
765	1236
	1237	+	SB511 HFLR Page 25
	1238	+	BOLD FACE denotes Committee Amendments. 1
	1239	+	2
	1240	+	3
	1241	+	4
	1242	+	5
	1243	+	6
	1244	+	7
	1245	+	8
	1246	+	9
	1247	+	10
	1248	+	11
	1249	+	12
	1250	+	13
	1251	+	14
	1252	+	15
	1253	+	16
	1254	+	17
	1255	+	18
	1256	+	19
	1257	+	20
	1258	+	21
	1259	+	22
	1260	+	23
	1261	+	24
	1262	+
766	1263		7. Descriptive materials accompanying the object which explain
767	1264		or depict its use as an object for the consumption of controlled
768	1265		dangerous substances;
769		-
770	1266		8. The manner in which the object is displayed for sale;
771		-
772	1267		9. Whether the owner, or anyone in control of the object, is a
773	1268		legitimate supplier of like or r elated items to the community, such
774	1269		as a licensed distributor or dealer of tobacco products;
775		-
776	1270		10. Direct or circumstantial evidence of the ratio of sales of
777	1271		the object or objects to the total sales of the business enterprise;
778		-
779	1272		11. The existence and scope o f legitimate uses for the object
780	1273		in the community; and
781		-
782	1274		12. Expert testimony concerning its use .
783		-
784	1275		Provided, nothing in this section shall apply to objects in the
785	1276		possession of harm-reduction services providers as authorized by
786	1277		Section 3 of this act .
787		-
788	1278		SECTION 3. NEW LAW A new section of law to be codified
789	1279		in the Oklahoma Statutes as Section 2 -1101 of Title 63, unless there
790	1280		is created a duplication in numbering, reads as follows:
791		-
792		-
793		-	ENR. S. B. NO. 511 Page 19
794	1281		A. Until July 1, 2026, the following are hereby authorize d to
795	1282		engage in harm-reduction services:
796		-
797	1283		1. Government entities including, but not limited to, the State
798	1284		Department of Health and the Department of Mental Health and
799	1285		Substance Abuse Services; provided, no state dollars shall be used
800	1286		to purchase hypodermic needles;
801	1287
	1288	+	SB511 HFLR Page 26
	1289	+	BOLD FACE denotes Committee Amendments. 1
	1290	+	2
	1291	+	3
	1292	+	4
	1293	+	5
	1294	+	6
	1295	+	7
	1296	+	8
	1297	+	9
	1298	+	10
	1299	+	11
	1300	+	12
	1301	+	13
	1302	+	14
	1303	+	15
	1304	+	16
	1305	+	17
	1306	+	18
	1307	+	19
	1308	+	20
	1309	+	21
	1310	+	22
	1311	+	23
	1312	+	24
	1313	+
802	1314		2. Religious institutions or churches;
803		-
804	1315		3. Nonprofit organizations;
805		-
806	1316		4. For-profit companies;
807		-
808	1317		5. Nongovernment entities partnering with a governmental
809	1318		agency; and
810		-
811	1319		6. Tribal governments.
812		-
813	1320		B. Those offering harm -reduction services shall register with
814	1321		the State Department of Health and may engage in the following
815	1322		activities in order to reduce the use of drugs, prevent outbreaks of
816	1323		infectious diseases and reduce morbidity among people who use
817	1324		injection drugs:
818		-
819	1325		1. Offer referrals and resources to tre at substance use
820	1326		disorders;
821		-
822	1327		2. Provide education on the risk of transmission of infectious
823	1328		diseases, including human immunodeficiency virus (HIV) and viral
824	1329		hepatitis;
825		-
826	1330		3. Rapid testing for HIV, hepatitis C and sexually transmitted
827	1331		infections (STIs);
828		-
829	1332		4. Referrals for medical and mental health services;
830		-
831	1333		5. Collect used hypodermic needles for safe disposal;
832		-
833	1334		6. Possess and distribute hypodermic needles, cleaning kits,
834	1335		test kits and opioid antagonists; and
835	1336
	1337	+	SB511 HFLR Page 27
	1338	+	BOLD FACE denotes Committee Amendments. 1
	1339	+	2
	1340	+	3
	1341	+	4
	1342	+	5
	1343	+	6
	1344	+	7
	1345	+	8
	1346	+	9
	1347	+	10
	1348	+	11
	1349	+	12
	1350	+	13
	1351	+	14
	1352	+	15
	1353	+	16
	1354	+	17
	1355	+	18
	1356	+	19
	1357	+	20
	1358	+	21
	1359	+	22
	1360	+	23
	1361	+	24
836	1362
837		-	ENR. S. B. NO. 511 Page 20
838	1363		7. Rapid substance testing products used, intended for use, or
839	1364		fashioned specifically for the use in identifying or analyzing the
840	1365		potency or toxicity of unknown substances.
841		-
842	1366		C. Registered providers of harm -reduction services shall report
843	1367		at least quarterly to the State Department of Health:
844		-
845	1368		1. The number of clients served including basic demographic
846	1369		information;
847		-
848	1370		2. Number and type of referrals provided;
849		-
850	1371		3. Number of syringes, test kits and antagonists distributed;
851		-
852	1372		4. Number of used syringes collected; and
853		-
854	1373		5. Number of rapid HIV and viral hepatitis test s performed
855	1374		including the number of reactive test results.
856		-
857	1375		D. The State Commissioner of Health shall promulgate rules for
858	1376		the implementation of this section.
859		-
860	1377		SECTION 4. It being immediately necessary for the preservation
861	1378		of the public peace, health or safety, an emergency is hereby
862	1379		declared to exist, by reason whereof this act shall take effect and
863	1380		be in full force from and after its passage and approval.
864	1381
865		-
866		-	ENR. S. B. NO. 511 Page 21
867		-	Passed the Senate the 3rd day of March, 2021.
868		-
869		-
870		-
871		-	Presiding Officer of the Senate
872		-
873		-
874		-	Passed the House of Representatives the 13th day of April, 2021.
875		-
876		-
877		-
878		-	Presiding Officer of the House
879		-	of Representatives
880		-
881		-	OFFICE OF THE GOVERNOR
882		-	Received by the Office of the Governor this _______ _____________
883		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
884		-	By: _______________________________ __
885		-	Approved by the Governor of the State of Oklahoma this _____ ____
886		-	day of ___________________, 20_______, at _______ o'clock _______ M.
887		-
888		-	_________________________________
889		-	Governor of the State of Oklahoma
890		-
891		-
892		-	OFFICE OF THE SECRETARY OF STATE
893		-	Received by the Office of the Secretary of State this _______ ___
894		-	day of __________________, 20 _______, at _______ o'clock _______ M.
895		-	By: _______________________________ __
	1382	+	COMMITTEE REPORT BY: COMMITTEE ON PUBLIC HEALTH, dated 03/31/2021 -
	1383	+	DO PASS, As Coauthored.